Exenatide

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Brain Injuries

Conditions

Brain Injuries

Trial Timeline

Aug 1, 2015 → Aug 1, 2017

NCT ID

NCT02058940

About Exenatide

Exenatide is a approved stage product being developed by AstraZeneca for Brain Injuries. The current trial status is completed. This product is registered under clinical trial identifier NCT02058940. Target conditions include Brain Injuries.

What happened to similar drugs?

4 of 17 similar drugs in Brain Injuries were approved

Approved (4) Terminated (2) Active (13)

✅RivastigmineNovartisApproved

✅Genotropin (PN-180,307) SomatropinPfizerApproved

✅Genotropin + PlaceboPfizerApproved

✅Dotarem® + Gadovist®/Gadavist®GuerbetApproved

🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

🔄temozolomideMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02058940	Approved	Completed	Aug 1, 2015	Aug 1, 2017	Brain Injuries
NCT02090673	Pre-clinical	Completed	Feb 1, 2009	Mar 1, 2014	Diabetes Mellitus Type 2
NCT00111540	Phase 3	Completed	Nov 1, 2002	Sep 1, 2006	Diabetes Mellitus, Type 2

Competing Products

20 competing products in Brain Injuries

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Endocrine therapy	Eli Lilly	Phase 1/2	39
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
Pembrolizumab + Lenvatinib	Eisai	Phase 2	42
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	27
GLIADEL	Eisai	Phase 2	35
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	29
abemaciclib + abemaciclib	Eli Lilly	Phase 2	39
JNJ-17299425	Johnson & Johnson	Phase 2	27
ABT-888	AbbVie	Phase 1	29
Veliparib + Placebo	AbbVie	Phase 2	35
Iressa (Gefitinib)	AstraZeneca	Phase 2	27
Trastuzumab deruxtecan	AstraZeneca	Phase 2	42
AZD5213	AstraZeneca	Phase 1	29
Vorinostat	Merck	Phase 1	29